Peptides/PT-141 (Bremelanotide)

PT-141 (Bremelanotide)

approved

Melanocortin receptor agonist for sexual desire and arousal enhancement

MC4R agonist
Type
SC injection / Nasal
Route
Yes — vendors & clinics
Available in Thailand
Yes — select clinics
Clinic therapy

Availability in Thailand

PT-141 is available from Thai peptide vendors in injectable form and offered at several Bangkok clinics specialising in sexual health and hormone therapy. Both injectable and nasal spray formulations are accessible in the Thai market.

Prescription: Not required from peptide vendors. Clinics may require consultation.

Legal status: Has regulatory approval in some markets for HSDD. Available as a research peptide in Thailand.

Where to Buy in Thailand

PT-141 is available as injectable vials and sometimes as nasal spray. Check vendor and clinic websites for current rates.

Vendors

Synergy Peptides

Bangkok

Premium GMP-certified peptides with verified COAs

View vendor →

Bangkok Health

Bangkok

Meditech peptides and performance compounds with domestic shipping

View vendor →

Clinics

H.U.M. Clinic

Bangkok

Sexual health and hormone therapy programs

View clinic →

FRESH GENETIQ

Bangkok

Peptide therapy programs

View clinic →

Overview

PT-141 (bremelanotide) is a melanocortin receptor agonist that works through the central nervous system to enhance sexual desire and arousal. Unlike PDE5 inhibitors which work mechanically on blood flow, PT-141 acts on dopamine pathways in the brain to increase genuine sexual desire — addressing the root cause of low libido rather than just the physical mechanics. It is effective in both men and women.

How It Works

Melanocortin-4 receptor activation

PT-141 activates melanocortin-4 (MC4R) receptors in the brain, specifically in areas controlling sexual arousal and desire. This stimulates dopaminergic pathways that increase genuine sexual desire, motivation, and arousal — not just mechanical erectile function.

Central nervous system action

Unlike erectile dysfunction medications that work on blood vessel dilation, PT-141 works centrally in the brain. This means it addresses desire itself, making it effective for people whose issue is low libido rather than physical inability. It is the only medication that directly activates brain pathways for sexual desire.

Effective in both sexes

PT-141 works through central mechanisms that are not sex-specific. It has shown effectiveness in both men with erectile dysfunction and women with hypoactive sexual desire disorder (HSDD) — one of the few treatments effective for female sexual dysfunction.

Protocol Quick Reference

starting Dose
1.75 mg subcutaneous, approximately 45 minutes before sexual activity
maintenance Dose
1.75 mg as needed. Maximum one dose per 24 hours. No more than 8 doses per month
escalation
Not applicable — standard dose per use
injection Sites
Subcutaneous — abdomen or thigh
full Titration
Not applicable — on-demand dosing
cycle Length
As needed. Not a daily protocol — used on-demand
storage
Refrigerated 2-8°C after reconstitution
reconstitution
Reconstitute lyophilised powder with bacteriostatic water. Nasal spray versions pre-mixed
timing
Approximately 45 minutes before desired effect. Effects last 6-12 hours
special Notes
Do NOT combine with PDE5 inhibitors (sildenafil, tadalafil) without medical consultation — risk of blood pressure drops. Nausea is the most common side effect and can be significant. Having food in your stomach may reduce nausea. Start with a lower dose (1 mg) to assess tolerance.

Benefits & Uses

  • Increased sexual desire: Works on brain chemistry to enhance genuine desire and motivation, not just physical mechanics
  • Effective for both men and women: Addresses low libido in both sexes through central dopaminergic pathways
  • Works when PDE5 inhibitors don't: Addresses a completely different mechanism — useful for those who don't respond to sildenafil/tadalafil
  • On-demand dosing: Taken 45 minutes before sexual activity as needed, not daily
  • Regulatory approval history: Has formal approval for hypoactive sexual desire disorder in premenopausal women in some markets

Side Effects

Common

  • Nausea — the most commonly reported side effect, can be significant in some users
  • Flushing (warmth, redness)
  • Headache
  • Mild increase in blood pressure (transient)

Less Common

  • Dizziness
  • Injection site reactions
  • Nasal congestion (with nasal spray)

Serious

  • Do NOT combine with PDE5 inhibitors without medical guidance — risk of hypotension
  • Can cause temporary increases in blood pressure — caution with uncontrolled hypertension
  • Not recommended for cardiovascular disease patients without medical clearance
  • Avoid in pregnancy

Related Peptides

FAQ

How is PT-141 different from Viagra/Cialis?

Completely different mechanism. Viagra and Cialis (PDE5 inhibitors) work on blood flow to produce an erection. PT-141 works on the brain to increase genuine sexual desire and arousal. PT-141 addresses wanting, not mechanics. Some people use PT-141 when PDE5 inhibitors don't address their actual issue, which is low desire.

Does PT-141 work for women?

Yes — it is one of the few treatments effective for female sexual dysfunction. It has formal approval in some markets for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works through central brain pathways that are not sex-specific.

How bad is the nausea?

Nausea is the most commonly reported side effect and can be significant for some users, especially at the standard 1.75 mg dose. Starting with a lower dose (1 mg) and having some food in your stomach may help. For most users, nausea subsides within 1-2 hours.

How often can I use PT-141?

It is recommended to use no more than one dose per 24-hour period and no more than 8 doses per month. It is an on-demand medication, not a daily treatment.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Peptides should be used under the guidance of a qualified healthcare professional. Individual results vary. Always consult your doctor before starting any peptide therapy.